Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RAS family of GTPases (KRAS, NRAS, HRAS) are small signaling proteins that act as molecular switches, cycling between an inactive GDP-bound state and an active GTP-bound state. Activation of RAS promotes downstream signaling through pathways such as MAPK/ERK, PI3K-AKT-mTOR, and Rac/Rho, leading to cell proliferation, survival, and other hallmarks of cancer. Mutations that constitutively activate RAS are common in many cancers and present significant therapeutic challenges.
Direct RAS inhibitors (e.g., G12C inhibitors), indirect inhibitors targeting downstream effectors (MEK, ERK, PI3K, mTOR)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAS Family GTPases (RAS).